Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Fluorouracil 25Oxaliplatin 24Irinotecan 24Leucovorin 23Bevacizumab 23Capecitabine 18Cetuximab 15Radiotherapy 6Gene Expression Profiling 5regorafenib 4Immunohistochemistry 4Gemcitabine 4Folfox protocol 4Colonoscopy 4Cisplatin 4Celecoxib 4Amplified Fragment Length Polymorphism Analysis 4Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Polymerase Chain Reaction 3Nivolumab 3Mitomycin 3Doxorubicin 3Cyclophosphamide 3Cholecalciferol 3Biopsy 3Aspirin 3sargramostim 2pembrolizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colonic Neoplasms × MK 2206 × Clear all
NCT01186705 2015-11-18

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡